The ameliorative effects of Moringa oleifera leaf extract on cardiovascular functions and osmotic fragility of wistar rats exposed to petrol vapour

The present study was aimed at evaluating the ameliorating effects of Moringa oleifera extract compared to captopril and candesartan cilexetil on cardiovascular functions and osmotic fragility of rats exposed to petrol vapour. Twenty five adult male Wistar rats (130g-200g) were randomly grouped to five with five rats in a group. Group 1 (control) was not exposed to petrol fume. Groups 2 (petrol only), was exposed to petrol fume only. Groups 3, 4 and 5 were pretreated with Moringa oleifera extract (40mg/kg), captopril (25 mg/kg) and candesartan (16mg/kg), respectively before exposure to petrol vapour, 10 minutes every day for eight weeks. All groups were given feed and water ad-libitum. Petrol vapour was generated by using human compressor nebulizer adopted for rats and connected to fume chamber where the rats were kept. The pretreatment were administered by oral cannula. At the end of the exposure, 0.2ml of blood samples obtained from individual rat in each group were suspended in separate sets of Phosphate buffer saline (PBS) solution of decreasing concentrations. Erythrocyte osmotic fragility (EOF) was determined by spectrophotometer. Electrocardiography was done using EDAN 10. There was significant increase (p<0.05) in EOF of the rats exposed to petrol vapour only. However, Moringa oleifera, captopril and candesartan cilexetil significantly ameliorated this effect. There was no significant difference in the amelioration of Moringa oleifera and candesartan cilexetil. There was absence of p-wave and significant increase in heart rate observed in the electrocardiogram of petrol only group, this was significantly restored in the Moringa oleifera, captopril and the candesartan cilexetil group. The results showed that exposure to petrol vapour elevated EOF, resulted in atria arrhythmia and increased heart rate. These effects were ameliorated by pretreatment with Moringa oleifera, captopril and candesartan cilexetil. The amelioration in Moringa oleifera was comparable with that of candesartan cilexetil suggesting that Moringa oleifera may be an Angiotensin II receptor blocker.Keywords: Candesartan cilexetil, Captopril, Moringa oleifera, Osmotic fragility, Petrol vapou

Enhancing Germination and Seedling Growth in Salt Stressed Maize Lines through Chemical Priming

This study aimed to investigate the tolerance level and the use of primers (H2O, KNO3, ascorbic acid and salicylic acid), in mitigating stress in maize in the newly released cultivars (SWAN-LSR-Y, BR9928-OMR-SR-Y and OMR-LSR-SY). Activities of SOD, APX, CAT and GSH and lipid peroxidation were investigated, to measure the biochemical response of the primed maize seeds. Maize seeds primed with KNO3 and ascorbic acid improved germination and anti-oxidative potential against ROS in ameliorating the salinity stress, while salicylic acid slowed germination. The same trend was followed in the seed vigour index and radicle length of seeds primed with ascorbic acid, which recorded the highest values. The control was observed to have the highest seed vigour index, while seeds primed with salicylic acid showed the least vigour index in the maize seeds.  Increased salinity stress showed adverse effects on all growth parameters. Of the maize cultivars tested, SWAN-LSR-Y showed the most tolerance to salinity stress, in terms of germination. Significant high enzymatic activities and lipid peroxidation were recorded in seeds primed with ascorbic acid and KNO3 show their importance in plant metabolic activities

Time to focus on outcome assessment tools for childhood vasculitis

Childhood systemic vasculitides are a group of rare diseases with multi-organ involvement and potentially devastating consequences. After establishment of new classification criteria (Ankara consensus conference in 2008), it is now time to establish measures for proper definition of activity and damage in childhood primary vasculitis. By comparison to adult vasculitis, there is no consensus for indices of activity and damage assessment in childhood vasculitis. Assessment of disease activity is likely to become a major area of interest in pediatric rheumatology in the near future. After defining the classification criteria for primary systemic childhood vasculitis, the next step was to perform a validation study using the original Birmingham vasculitis activity score as well as the disease extent index to measure disease activity in childhood vasculitis. Presently, there are efforts in place to develop a pediatric vasculitis activity score. This paper reviews the current understanding about the assessment tools (i.e., clinical features, laboratory tests, radiologic assessments, etc.) widely used for evaluation of the disease activity and damage status of the children with vasculitis

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049